Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Mediwound stock

MDWD
IL0011316309
A110TG

Price

16.60
Today +/-
+0.35
Today %
+2.25 %

Mediwound stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Mediwound stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Mediwound stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Mediwound stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Mediwound's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Mediwound Stock Price History

DateMediwound Price
2/27/202516.60 undefined
2/26/202516.23 undefined
2/25/202515.98 undefined
2/24/202516.69 undefined
2/23/202518.00 undefined
2/20/202517.68 undefined
2/19/202518.61 undefined
2/18/202518.48 undefined
2/17/202518.28 undefined
2/13/202518.76 undefined
2/12/202518.62 undefined
2/11/202517.89 undefined
2/10/202517.26 undefined
2/9/202517.54 undefined
2/6/202518.11 undefined
2/5/202519.50 undefined
2/4/202520.33 undefined
2/3/202519.50 undefined
2/2/202519.15 undefined

Mediwound Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mediwound, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mediwound from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mediwound’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mediwound. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mediwound’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mediwound’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mediwound’s growth potential.

Mediwound Revenue, EBIT and net profit per share

DateMediwound RevenueMediwound EBITMediwound Net Income
2030e193.59 M undefined0 undefined48.87 M undefined
2029e148.84 M undefined43.01 M undefined28.39 M undefined
2028e104.89 M undefined20.82 M undefined10.35 M undefined
2027e66.02 M undefined411,570 undefined-9.02 M undefined
2026e32.21 M undefined-16.03 M undefined-17.66 M undefined
2025e25.86 M undefined-23.29 M undefined-25.46 M undefined
2024e20.58 M undefined-19.42 M undefined-36.87 M undefined
202318.69 M undefined-15.5 M undefined-6.72 M undefined
202226.5 M undefined-7.46 M undefined-19.6 M undefined
202123.76 M undefined-11.22 M undefined-13.55 M undefined
202021.76 M undefined-8.84 M undefined-9.2 M undefined
201931.79 M undefined5.66 M undefined4.96 M undefined
20183.4 M undefined-10.75 M undefined-1.06 M undefined
20172.5 M undefined-13.69 M undefined-22.15 M undefined
20161.56 M undefined-20.16 M undefined-18.89 M undefined
2015600,000 undefined-21.23 M undefined-22.09 M undefined
2014260,000 undefined-21.43 M undefined-18.88 M undefined
20130 undefined-7.58 M undefined-15.35 M undefined
20120 undefined-2.73 M undefined10.94 M undefined
20110 undefined-4.29 M undefined-6.17 M undefined

Mediwound Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000123312123261820253266104148193
------100.0050.00933.33-32.269.5213.04-30.7711.1125.0028.00106.2557.5842.3130.41
-----300.00150.0033.3361.2933.3334.7850.0016.6715.0012.009.384.552.882.031.55
000-2-100119781330000000
-610-15-18-22-18-22-14-9-13-19-6-36-25-17-9102848
--266.67-250.0020.0022.22-18.1822.22-95.45-500.00-325.0044.4446.15-68.42500.00-30.56-32.00-47.06-211.11180.0071.43
2.242.462.242.853.13.123.333.873.883.893.894.999.010000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Mediwound Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mediwound is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
3.660.349.5564.8545.7730.0336.0723.6329.2821.411.0533.941.71
0000.060.240.330.370.564.112.772.139.333.7
0001.962.472.193.076.710.450.070.140.20.72
0.490.8601.421.720.841.891.681.611.381.21.962.85
40250510210210220130130180570440460722
4.191.4510.0668.550.4133.6141.5332.7135.6326.1914.9645.8549.7
1.631.271.141.091.041.281.922.024.534.514.033.5815.93
300200170190100605000000
000000000028018050
5.445.0910.950.90.770.640.50.430.360.30.230.17
0000000000000
0.4215.820.420.420000000.190.180.62
7.5222.182.762.632.132.152.622.574.964.874.84.1716.76
11.7123.6312.8271.1352.5435.7644.1535.2840.5931.0619.7650.0266.46
                         
1010106060608080808080140184
47.3247.6962.23109.12111.8114.98138.99139.64140.87142.19143.87178.88206.25
-43-32.06-47.41-66.29-88.38-107.26-129.41-130.72-125.76-134.96-148.51-168.11-174.82
00-0.03-0.02-0.02-0.01-0.04-0.03-0.02-0.04-0.02-0.01-0.02
0000000000000
4.3315.6414.842.8723.467.779.628.9715.177.27-4.5810.931.6
0.750.781.181.211.121.463.252.724.072.994.695.665.53
0.90.70.682.193.723.461.621.531.721.911.642.472.11
0.510.330.160.490.370.470.560.654.012.83.793.42.83
01.5600000000000
00000000570570600530361
2.163.372.023.895.215.395.434.910.378.2710.7212.0610.83
000000002.011.741.390.856.35
0000000000000
5.616.4432.6124.3523.8522.6129.0821.4113.0413.7912.2126.217.69
5.616.4432.6124.3523.8522.6129.0821.4115.0515.5313.627.0524.03
7.779.8134.6328.2429.062834.5126.3125.4223.824.3239.1134.86
12.125.4549.4371.1152.5235.7744.1335.2840.5931.0719.7450.0166.46
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Mediwound provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Mediwound's financial health and stability.

Assets

Mediwound's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Mediwound must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Mediwound after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Mediwound's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-610-15-18-22-18-22-14-9-13-19-6
000000001,0001,0001,0001,0001,000
0000000000000
0-11001-2-1400-72
3-1346438-10-12415-5
0000000000000
0000000000000
-2-4-9-16-19-16-16-128-6-8-11-10
000000-100000-6
-30-2-373610-17-61730-34
-20-2-363621-16-61840-27
0000000000000
0130000000000
601672002200003824
71197200230-10-13522
------------1.00-1.00
0000000000000
0-361817-137-29010-622-22
-3.81-5.14-10.1-16.89-20.01-17.15-17.54-12.687.5-7.82-9.41-12.45-16.93
0000000000000

Mediwound stock margins

The Mediwound margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mediwound. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mediwound.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mediwound's sales revenue. A higher gross margin percentage indicates that the Mediwound retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mediwound's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mediwound's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mediwound's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mediwound. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mediwound's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mediwound Margin History

Mediwound Gross marginMediwound Profit marginMediwound EBIT marginMediwound Profit margin
2030e19.15 %0 %25.24 %
2029e19.15 %28.89 %19.08 %
2028e19.15 %19.85 %9.86 %
2027e19.15 %0.62 %-13.67 %
2026e19.15 %-49.77 %-54.84 %
2025e19.15 %-90.06 %-98.47 %
2024e19.15 %-94.36 %-179.13 %
202319.15 %-82.96 %-35.94 %
202249.7 %-28.15 %-73.96 %
202136.91 %-47.22 %-57.03 %
202034.7 %-40.63 %-42.28 %
201962.72 %17.8 %15.6 %
201838.53 %-316.18 %-31.18 %
201736.8 %-547.6 %-886 %
2016-38.46 %-1,292.31 %-1,210.9 %
2015-320 %-3,538.33 %-3,681.67 %
2014-973.08 %-8,242.31 %-7,261.54 %
201319.15 %0 %0 %
201219.15 %0 %0 %
201119.15 %0 %0 %

Mediwound Stock Sales Revenue, EBIT, Earnings per Share

The Mediwound earnings per share therefore indicates how much revenue Mediwound has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mediwound earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mediwound's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mediwound’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mediwound's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mediwound Revenue, EBIT and net profit per share

DateMediwound Sales per ShareMediwound EBIT per shareMediwound Earnings per Share
2030e17.94 undefined0 undefined4.53 undefined
2029e13.79 undefined0 undefined2.63 undefined
2028e9.72 undefined0 undefined0.96 undefined
2027e6.12 undefined0 undefined-0.84 undefined
2026e2.99 undefined0 undefined-1.64 undefined
2025e2.4 undefined0 undefined-2.36 undefined
2024e1.91 undefined0 undefined-3.42 undefined
20232.07 undefined-1.72 undefined-0.75 undefined
20225.31 undefined-1.49 undefined-3.93 undefined
20216.11 undefined-2.88 undefined-3.48 undefined
20205.59 undefined-2.27 undefined-2.37 undefined
20198.19 undefined1.46 undefined1.28 undefined
20180.88 undefined-2.78 undefined-0.27 undefined
20170.75 undefined-4.11 undefined-6.65 undefined
20160.5 undefined-6.46 undefined-6.05 undefined
20150.19 undefined-6.85 undefined-7.13 undefined
20140.09 undefined-7.52 undefined-6.62 undefined
20130 undefined-3.38 undefined-6.85 undefined
20120 undefined-1.11 undefined4.45 undefined
20110 undefined-1.92 undefined-2.75 undefined

Mediwound business model

Mediwound Ltd is an Israeli company specializing in the development and marketing of therapies for chronic and acute wounds. The company was founded in 2000 and is headquartered in Yavne, Israel. Its history began with the idea of developing an innovative treatment method for burns. The company collaborated closely with the Israeli Ministry of Defense to find a better method for wound treatment. The result was the product NexoBrid, an enzymatic debridement treatment that aims to remove dead tissue from burn wounds to enable faster healing. Mediwound's business model is to develop and market innovative drugs and therapy solutions for wounds. The company operates in several areas, including burn wounds, chronic wounds, and trauma wounds. In the burn wounds sector, Mediwound offers the product NexoBrid, which enzymatically removes dead tissue from burns and eliminates neurotoxic substances that can damage wound healing if left in the tissue for too long. NexoBrid is already approved in several countries, including the USA and European countries. In the chronic wounds sector, Mediwound offers the product EscharEx, which is used to treat chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. EscharEx also uses an enzymatic approach and aims to remove dead tissue to enable the body's natural healing process. There are plans to launch EscharEx in Europe in the second half of 2021. Mediwound also operates in the trauma wounds sector and received the product MWPC003 in Europe in 2020. It is a novel enzymatic debriding product that can be used in the integrated therapy of complex trauma wounds with additional topical treatment options. Through the development of innovative therapies and drugs, Mediwound has established itself as a reliable partner in wound treatment. The company continues to focus on innovation and plans to expand its product range in the future. Overall, Mediwound Ltd is a groundbreaking company in the field of wound care. The company's products and solutions contribute to faster and more effective wound healing, improving the lives of patients worldwide. Mediwound is one of the most popular companies on Eulerpool.com.

Mediwound SWOT Analysis

Strengths

Mediwound Ltd possesses several strengths that contribute to its success in the market. The company's advanced wound care products and technologies lead the industry, providing innovative solutions for various types of wounds. Furthermore, Mediwound's strong research and development capabilities enable continuous product improvement and expansion, strengthening its competitive advantage. The company's extensive experience in the wound care market and established relationships with healthcare professionals and key stakeholders further enhance its market position.

Weaknesses

Despite its strengths, Mediwound Ltd faces certain weaknesses that pose challenges. The company heavily relies on a limited range of products, which may make it vulnerable to market shifts or changes in customer preferences. Additionally, Mediwound's dependency on external suppliers for raw materials and manufacturing processes can disrupt the supply chain, potentially impacting production and delivery timelines. Addressing these weaknesses through diversification strategies and supplier management is crucial for sustained success.

Opportunities

Mediwound Ltd operates in an industry with several growth opportunities. The increasing prevalence of chronic wounds and rising healthcare expenditure present an expanding market for Mediwound's wound care solutions. The company can seize the opportunity to expand its product portfolio and diversify into new markets and segments, such as diabetic wound care or regenerative medicine. Moreover, partnerships or collaborations with healthcare organizations and research institutions can fuel innovation and provide access to untapped markets.

Threats

Mediwound Ltd also faces threats that could affect its business operations. Intense competition within the wound care industry, where numerous well-established players exist, poses challenges for market share and pricing. Additionally, regulatory requirements and compliance measures may increase operational costs and restrict product development or approval processes. The potential emergence of alternative therapies or disruptive technologies could also impact Mediwound's market position. Continual monitoring of the competitive landscape and adapting swiftly to regulatory changes is essential to mitigate threats effectively.

Mediwound Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Mediwound Revenue by Segment

Segmente20232021
USA13.08 M USD18.1 M USD
EU and other international markets5.61 M USD5.66 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mediwound Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Mediwound historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mediwound shares outstanding

The number of shares was Mediwound in 2024 — This indicates how many shares 9.013 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mediwound earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mediwound's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mediwound’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mediwound's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mediwound stock splits

In Mediwound's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Mediwound.

Mediwound latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.45 -0.98  (-116.72 %)2024 Q3
6/30/2024-0.43 -0.68  (-58.73 %)2024 Q2
3/31/2024-0.41 -1.05  (-153.13 %)2024 Q1
12/31/2023-0.23 -0.19  (18.14 %)2023 Q4
9/30/2023-0.45 -0.24  (46.83 %)2023 Q3
6/30/2023-0.41 0.1  (124.31 %)2023 Q2
3/31/2023-0.31 -0.44  (-41.43 %)2023 Q1
12/31/2022-0.6 -1.18  (-96.08 %)2022 Q4
9/30/2022-0.71 -0.91  (-27.45 %)2022 Q3
6/30/2022-0.69 -0.84  (-21.7 %)2022 Q2
1
2
3
4
...
5

Mediwound shareholders

%
Name
Stocks
Change
Date
13.73050 % Clal Biotechnology Industries Ltd1,481,52107/17/2024
8.08242 % Investor AB872,093012/31/2024
7.89028 % Yelin Lapidot Provident Funds Management Ltd851,361100,61812/31/2024
5.82067 % Rosalind Advisors, Inc.628,050012/31/2024
5.10894 % Deep Insight Limited Partnership551,255142,85812/31/2023
5.10894 % Israel Biotech Fund551,255142,85812/31/2023
3.70551 % BlackRock Institutional Trust Company, N.A.399,8256,63012/31/2024
1.53597 % Balyasny Asset Management LP165,731-512/31/2024
1.38044 % Essex Investment Management Company, LLC148,94935,01212/31/2024
1.12317 % Sargent Investment Group, LLC121,1903,99812/31/2024
1
2
3
4
5
...
10

Mediwound Executives and Management Board

Mr. Sharon Malka

(51)
Mediwound Chief Executive Officer
Compensation 770,000

Dr. Lior Rosenberg

(76)
Mediwound Chief Medical Technology Officer (since 2001)
Compensation 485,000

Dr. Ety Klinger

(60)
Mediwound Chief Research and Development Officer
Compensation 435,000

Mr. Boaz Gur-Lavie

(48)
Mediwound Chief Financial Officer
Compensation 404,000

Mr. Yaron Meyer

(43)
Mediwound Executive Vice President, General Counsel, Corporate Secretary
Compensation 364,000
1
2
3

Mediwound Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Clal Biotechnology Stock
Clal Biotechnology
SupplierCustomer 0,520,510,740,770,20
S2medical B Stock
S2medical B
SupplierCustomer0,820,420,420,700,750,61
Kaken Pharmaceutical Stock
Kaken Pharmaceutical
SupplierCustomer0,580,360,070,580,830,21
Vericel Stock
Vericel
SupplierCustomer0,160,440,570,460,920,36
1

Most common questions regarding Mediwound

What values and corporate philosophy does Mediwound represent?

Mediwound Ltd is a renowned company that embodies key values and a strong corporate philosophy. With a focus on innovation, Mediwound is committed to developing cutting-edge therapeutic solutions for severe burns, chronic wounds, and other challenging conditions. The company places great importance on integrity, transparency, and ethical practices, ensuring that patients and healthcare professionals can trust their products and services. Mediwound's dedication to quality, combined with a patient-centric approach, fosters long-term relationships and positions the company as a reliable leader in the medical industry. Through continuous research and development, Mediwound Ltd remains dedicated to improving patient outcomes and enhancing the quality of life for individuals worldwide.

In which countries and regions is Mediwound primarily present?

Mediwound Ltd is primarily present in Israel, where its headquarters are located. As a biopharmaceutical company, Mediwound focuses on the development and commercialization of novel therapies for severe burns and chronic wound management. It operates globally, expanding its presence through partnerships and collaborations with leading healthcare institutions, organizations, and distributors. With a strong emphasis on innovation, Mediwound aims to provide advanced solutions and improve patients' quality of life worldwide.

What significant milestones has the company Mediwound achieved?

Mediwound Ltd has achieved several significant milestones. Notably, the company successfully developed NexoBrid, a topically-administered enzymatic debridement agent for the removal of dead tissue in severe burns. In 2014, NexoBrid received marketing approval in Europe, marking a major accomplishment. Additionally, Mediwound Ltd secured marketing authorization from the US FDA in 2020, allowing them to commercialize NexoBrid in the United States. The company has also performed numerous clinical trials, demonstrating the safety and efficacy of their products. With these achievements, Mediwound Ltd has established itself as a pioneering leader in advanced wound care solutions.

What is the history and background of the company Mediwound?

MediWound Ltd is a leading biopharmaceutical company specializing in innovative therapeutics for acute and chronic wound healing. Founded in 2001, the company's mission is to provide advanced treatments that help patients' wounds heal faster and more effectively. With a focus on developing and commercializing innovative products, MediWound has built a strong reputation in the medical field. Their flagship product, NexoBrid, is an enzymatic debriding agent approved for treating severe burns. MediWound has a dedicated team of experts and continues to expand its product portfolio to address unmet medical needs in wound care. This commitment has made them a trusted name in the industry.

Who are the main competitors of Mediwound in the market?

The main competitors of Mediwound Ltd in the market include companies such as Vericel Corporation, Organogenesis Holdings Inc., and Avita Medical Ltd. These companies also specialize in advanced wound care treatments and products, providing competition for Mediwound in the industry. However, Mediwound has established a strong presence with its innovative product, NexoBrid, which offers a unique enzymatic debridement therapy. With its effective and efficient wound debridement solution, Mediwound remains a prominent player in the market, even amidst competition from these companies.

In which industries is Mediwound primarily active?

Mediwound Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Mediwound?

Mediwound Ltd operates with a business model focused on developing, producing, and commercializing innovative products for the treatment of severe burns, chronic and acute wounds, and other skin-related conditions. By leveraging advanced biotechnology, Mediwound is dedicated to improving patients' lives through its innovative therapies. With a strategic emphasis on research and development, the company aims to address unmet medical needs and provide effective solutions for wound management. Mediwound's commitment to advancing medical treatments positions it as a leader in the field, contributing to the betterment of patients' quality of life worldwide.

What is the P/E ratio of Mediwound 2025?

The Mediwound P/E ratio is -5.88.

What is the P/S ratio of Mediwound 2025?

The Mediwound P/S ratio is 5.79.

What is the Quality Investing of Mediwound?

The Quality Investing for Mediwound is 4/10.

What is the revenue of Mediwound 2025?

The expected Mediwound revenue is 25.86 M USD.

How high is the profit of Mediwound 2025?

The expected Mediwound profit is -25.46 M USD.

What is the business model of Mediwound

MediWound Ltd is an innovative biopharmaceutical company based in Israel, focusing on the development and marketing of advanced wound care therapies. The company offers various products and services, including the well-known MEDICOL Gel, NexoBrid, and other wound treatment products. NexoBrid is a unique enzymatic product that swiftly and effectively removes burned skin. It has proven to be safe and effective in treating severe thermal injuries and has been successfully tested in multiple clinical studies. The product is approved in both Europe and the United States and is successfully marketed worldwide. MEDICOL Gel is a scientifically advanced hydrogel specifically designed for wound care. It utilizes innovative technology for moisture regulation and pain relief and promotes rapid wound healing. The gel is an essential component of wound care and has been proven effective and safe in numerous clinical studies. Additionally, MediWound also offers other products, including TelfaClear, an innovative transparent dressing material that works excellently for wound treatment, and Curabond, a strong and flexible wound adhesive particularly suitable for post-surgical wound care. MediWound aims to revolutionize wound care and improve the quality of life for people worldwide. The company has an experienced leadership team and a strong network of partners in the medical industry. It is supported by a dedicated team of researchers, scientists, and physicians, working closely with leading universities and medical institutions to develop innovative solutions for wound healing. MediWound's business model is based on the development and marketing of advanced wound care therapies. The company focuses on researching and developing new products and services and collaborates closely with customers and partners to ensure its products meet the needs of patients. MediWound's commitment to innovation and excellence has earned it a strong presence in the medical industry. It has formed partnerships with leading companies in the field and also works closely with government agencies and medical facilities to distribute its products worldwide. Overall, MediWound is a leading biopharmaceutical company focusing on the development and marketing of innovative wound care therapies. With its strong partnerships, highly skilled employees, and innovative capabilities, the company is well positioned to revolutionize the wound care market in the future.

What is the Mediwound dividend?

Mediwound pays a dividend of 0 USD distributed over payouts per year.

How often does Mediwound pay dividends?

The dividend cannot currently be calculated for Mediwound or the company does not pay out a dividend.

What is the Mediwound ISIN?

The ISIN of Mediwound is IL0011316309.

What is the Mediwound WKN?

The WKN of Mediwound is A110TG.

What is the Mediwound ticker?

The ticker of Mediwound is MDWD.

How much dividend does Mediwound pay?

Over the past 12 months, Mediwound paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mediwound is expected to pay a dividend of 0 USD.

What is the dividend yield of Mediwound?

The current dividend yield of Mediwound is .

When does Mediwound pay dividends?

Mediwound pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mediwound?

Mediwound paid dividends every year for the past 0 years.

What is the dividend of Mediwound?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mediwound located?

Mediwound is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mediwound kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mediwound from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Mediwound pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Mediwound in the year 2024?

In the year 2024, Mediwound distributed 0 USD as dividends.

In which currency does Mediwound pay out the dividend?

The dividends of Mediwound are distributed in USD.

All fundamentals about Mediwound

Our stock analysis for Mediwound Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mediwound Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.